BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo FF, Cui JW. The Role of Tumor-Infiltrating B Cells in Tumor Immunity. J Oncol 2019;2019:2592419. [PMID: 31662750 DOI: 10.1155/2019/2592419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9:1818437. [PMID: 33117602 DOI: 10.1080/2162402X.2020.1818437] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Luthra R, Datta S, Roy A. Role of Different Peptides for Cancer Immunotherapy. Int J Pept Res Ther 2021;27:2777-93. [DOI: 10.1007/s10989-021-10289-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One 2017;12:e0177919. [PMID: 28591206 DOI: 10.1371/journal.pone.0177919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Wallis J, Katti P, Martin AM, Hills T, Seymour LW, Shenton DP, Carlisle RC. A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. Eur J Pharm Sci 2020;152:105456. [PMID: 32653563 DOI: 10.1016/j.ejps.2020.105456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res 2019;25:3495-507. [PMID: 30804020 DOI: 10.1158/1078-0432.CCR-18-3997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
8 Briquez PS, Hauert S, de Titta A, Gray LT, Alpar AT, Swartz MA, Hubbell JA. Engineering Targeting Materials for Therapeutic Cancer Vaccines. Front Bioeng Biotechnol. 2020;8:19. [PMID: 32117911 DOI: 10.3389/fbioe.2020.00019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Hoo WPY, Siak PY, Alias NAR, Wong JJ, Tan EW, Song AA, Abdul Rahim R, In LLA. K-ras peptide mimotope induces a humoral immune response against G12V K-ras antigen in BALB/c mice. APJMBB. [DOI: 10.35118/apjmbb.2020.028.3.03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Moreno Ayala MA, Gottardo MF, Asad AS, Zuccato C, Nicola A, Seilicovich A, Candolfi M. Immunotherapy for the treatment of breast cancer. Expert Opin Biol Ther 2017;17:797-812. [PMID: 28446053 DOI: 10.1080/14712598.2017.1324566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Cui N, Shi J, Yang C. HER2-Based Immunotherapy for Breast Cancer. Cancer Biother Radiopharm 2018;33:169-75. [PMID: 29874101 DOI: 10.1089/cbr.2017.2327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Nordin ML, Mohamad Norpi AS, Ng PY, Yusoff K, Abu N, Lim KP, Azmi F. HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model. Cancers (Basel) 2021;13:4958. [PMID: 34638441 DOI: 10.3390/cancers13194958] [Reference Citation Analysis]
13 Wang JZ, Zhang YH, Guo XH, Zhang HY, Zhang Y. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol 2016;36:73-85. [PMID: 27111515 DOI: 10.1016/j.intimp.2016.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
14 Zhang L, Huang Y, Lindstrom AR, Lin TY, Lam KS, Li Y. Peptide-based materials for cancer immunotherapy. Theranostics 2019;9:7807-25. [PMID: 31695802 DOI: 10.7150/thno.37194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]